Biotech News
Related news
ALKSAlkermes plc2026-06-03 20:05 EST
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
PRAXPraxis Precision Medicines2026-06-04 20:01 EST
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
SUPNSupernus2026-05-27 20:30 EST
Supernus Pharmaceuticals to Participate in June Investor Conferences
ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST
Teva to Present at the Goldman Sachs Global Healthcare Conference
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
HRMYHarmony Biosciences2026-05-27 12:05 EST
Harmony Biosciences to Participate in Upcoming Investor Conferences
ABOSAcumen Pharmaceuticals2026-07-15 11:30 EST
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
ECORelectroCore2026-06-17 12:00 EST
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
NBIXNeurocrine Biosciences2026-05-26 20:01 EST
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
Supernus
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...
Recent company news
SUPNSupernus2026-08-03 10:35 EST
Supernus Announces Second Quarter 2026 Financial Results
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
SUPNSupernus2026-07-22 21:05 EST
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
SUPNSupernus2026-07-14 12:30 EST
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
SUPNSupernus2026-05-27 20:30 EST
Supernus Pharmaceuticals to Participate in June Investor Conferences
Stock data
- Close
- 45.85 USD
- Market cap
- 2.56B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States